Early Phase 1 Heart Disease Trial, Recruiting NCT06813339 Sponsor: Cyclarity Therapeutics, Inc. Condition: Heart Disease
Back to Heart Disease

Early Phase 1 Heart Disease Trial, Recruiting

NCT06813339
Recruiting Early Phase 1 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For all participants:

  • The person is able to understand what the study involves and agrees to take part in writing.
  • The person is able to follow the study schedule and complete all required assessments.

For healthy participants (certain parts of the trial):

  • Adults (male or female) aged 18 to 65 years at the time of screening.
  • People with a body mass index (a measure of body weight relative to height) between 18 and 32, and a body weight between 50 kg and 120 kg.
  • People who smoke fewer than 10 nicotine-containing products per month, and who have not used any tobacco or nicotine products (including quit-smoking aids) for at least 2 weeks before the first dose, confirmed by a negative nicotine test.
  • People who are generally in good health, with kidney-related test results within an acceptable range and no significant health concerns identified during screening, as assessed by the lead doctor.

For participants with a history of a heart condition (another part of the trial):

  • Adults (male or female) aged 40 to 79 years, who have been diagnosed with acute coronary syndrome (a serious heart condition involving reduced blood flow to the heart), at least 12 months after the event occurred.
  • People with a body mass index of 18 or above.
  • People who are medically stable with no significant health concerns found during screening, as assessed by the lead doctor.
  • People who have been on a steady, unchanged treatment plan for their heart condition — including medicines such as statins, blood thinners, or anti-clotting medications — for at least 3 months before screening, with no planned changes to that treatment during the study.

Who may not be able to join:

  • No formal exclusion criteria were listed in the information provided. (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Phone: (707) 200-3610

Australian sites

CMAX Clinical Research, Adelaide, South Australia
+61(08)70887900

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Cyclarity Therapeutics, Inc.
Registry
ClinicalTrials.gov
Start date
25 February 2025
Est. completion
30 December 2026

Where this trial is recruiting

🇦🇺 Australia

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Safety outcome measures (Adverse Events); Safety outcome measures (Vital Signs: Systolic Blood Pressure); Safety outcome measures (Vital Signs: Diastolic Blood Pressure); Safety outcome measures (Vital signs: Heart Rate); Safety outcome measures (Vital signs: Respiratory Rate); Safety outcome measures (Vital signs: Temperature); Safety outcome measures (Clinical Laboratory Parameters); Safety outcome measures (ECG QTCF Interval); Safety outcome measures (Injection site reactions); Safety outcome measures (Audiometry: PTA); Safety outcome measures (Audiometry: HFA); Safety outcome measures (Aud...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov